C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to ...

The company received a certificate of Good Manufacturing Practice (GMP) compliance following an inspection of their Montreal facility by the European Medicines AgencyMONTRÉAL, Feb. 19, 2025 (GLOBE NEW ...

C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.

Q1 2025 Earnings Call Transcript February 13, 2025 Applied DNA Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $-0.32. Operator: Good day, and welcome to ...

Well, a global provider of genomic library and multiplexing workflow solutions, today announced the early access availability of the new MosaiXtm Library Prep Kit, designed for demanding applications ...

On-demand video webcast now available here IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation ("enVVeno" or the "Company"), a company setting new standards of care for the ...

PAHO/WHO guidelines in procuring medicines from alternative sources demands the production of GMP certificates and certificate ... about the disease and the medicine by holding scientific meetings ...

MONTRÉAL — C3i Center obtains regulatory approval from the EMA (European Medicine Agency) to produce cell therapy treatments for the European market. C3i, therefore, obtains a certificate of GMP ...

The Stability Program is being conducted in collaboration with HYTN’s GMP-licensed laboratory partner. Upon successful completion, HYTN expects to provide an initial six-month stability statement for ...

(hereafter "NX Taiwan"), a group company of NIPPON EXPRESS HOLDINGS, INC., obtained certification on Wednesday, December 18, 2024 from the Taiwan Food and Drug Administration (TFDA) for the quality ...

It is well-known that ketamine is an essential medicine used for anesthesia and analgesia (pain relief) and has been used as a sedative and painkiller in hospital settings. Outside of the US FDA and ...

NKGen Biotech, Inc, a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, announced that the ...